Leaked news from the future.
Tap to receive
A Biologics License Application for intismeran autogene will be submitted to the FDA by June 30, 2027. Moderna and Merck will move the individualized neoantigen therapy from trials toward licensure after running the fully enrolled Phase III INTerpath-001 program and leveraging Breakthrough Therapy…